Posts

Serapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from China

on

Boundless Bio agrees to reverse merger with Serapha Bio in $230M gene‑editing deal

on

Wave aims for monthly dosing with RNA editing treatment for AATD now targets a monthly injection schedule for its WVE‑006 program in AATD.

on

Beam's Base Editor Advances to Pivotal Development on Back of Impressive AATD Data

on

GSK Returns Rights to Wave Life Sciences' WVE-006 RNA Editing Program for AATD

on

Tessera Therapeutics Strikes $150M Partnership with Regeneron for Gene Writing Therapy

on

Tessera Therapeutics Advances Gene Writing Technology with Major Funding and Strategic Partnerships

on

Korro Bio Abandons Lead Genetic Disease Drug Candidate KRRO-110 After Disappointing Trial Data

on

Sanofi’s efdoralprin alfa (INBRX-101) achieves all endpoints in Phase 2 alpha-1 antitrypsin deficiency (AATD) trial

on

Wave RNA Editing Restores Enzyme in Genetic Disorder but Fails to Impress Investors

on

Wave Life Sciences Shares Dip After Mixed Data Update on GSK-Partnered AATD Therapy

on

Korro Bio Lays Off 20% of Workforce to Extend Runway for Genetic Medicine Trials and Novo Nordisk Partnership

on